vs
Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and Day One Biopharmaceuticals, Inc. (DAWN). Click either name above to swap in a different company.
Caledonia Mining Corp Plc is the larger business by last-quarter revenue ($46.9M vs $39.8M, roughly 1.2× Day One Biopharmaceuticals, Inc.). Caledonia Mining Corp Plc runs the higher net margin — 7.0% vs -49.6%, a 56.6% gap on every dollar of revenue. On growth, Caledonia Mining Corp Plc posted the faster year-over-year revenue change (13.8% vs -57.6%).
Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
CMCL vs DAWN — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.9M | $39.8M |
| Net Profit | $3.3M | $-19.7M |
| Gross Margin | 41.2% | — |
| Operating Margin | 18.6% | -60.9% |
| Net Margin | 7.0% | -49.6% |
| Revenue YoY | 13.8% | -57.6% |
| Net Profit YoY | -33.3% | -153.3% |
| EPS (diluted) | $0.13 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $39.8M | ||
| Q2 25 | — | $33.9M | ||
| Q1 25 | — | $30.8M | ||
| Q3 24 | $46.9M | $93.8M | ||
| Q2 24 | $50.1M | — | ||
| Q1 24 | $38.5M | $0 | ||
| Q4 23 | $38.7M | — | ||
| Q3 23 | $41.2M | $0 |
| Q3 25 | — | $-19.7M | ||
| Q2 25 | — | $-30.3M | ||
| Q1 25 | — | $-36.0M | ||
| Q3 24 | $3.3M | $37.0M | ||
| Q2 24 | $10.2M | — | ||
| Q1 24 | $2.1M | $-62.4M | ||
| Q4 23 | $-2.6M | — | ||
| Q3 23 | $4.9M | $-46.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 41.2% | — | ||
| Q2 24 | 45.8% | — | ||
| Q1 24 | 35.9% | — | ||
| Q4 23 | 27.3% | — | ||
| Q3 23 | 34.3% | — |
| Q3 25 | — | -60.9% | ||
| Q2 25 | — | -103.1% | ||
| Q1 25 | — | -133.5% | ||
| Q3 24 | 18.6% | 31.6% | ||
| Q2 24 | 32.2% | — | ||
| Q1 24 | 13.8% | — | ||
| Q4 23 | 6.0% | — | ||
| Q3 23 | 22.4% | — |
| Q3 25 | — | -49.6% | ||
| Q2 25 | — | -89.4% | ||
| Q1 25 | — | -117.0% | ||
| Q3 24 | 7.0% | 39.5% | ||
| Q2 24 | 20.3% | — | ||
| Q1 24 | 5.4% | — | ||
| Q4 23 | -6.7% | — | ||
| Q3 23 | 12.0% | — |
| Q3 25 | — | $-0.19 | ||
| Q2 25 | — | $-0.29 | ||
| Q1 25 | — | $-0.35 | ||
| Q3 24 | $0.13 | $0.38 | ||
| Q2 24 | $0.42 | — | ||
| Q1 24 | $0.07 | $-0.72 | ||
| Q4 23 | $-0.19 | — | ||
| Q3 23 | $0.21 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.2M | $451.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.0M | $450.9M |
| Total Assets | $339.7M | $513.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $451.6M | ||
| Q2 25 | — | $453.1M | ||
| Q1 25 | — | $473.0M | ||
| Q3 24 | $7.2M | $558.4M | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.8M | $317.9M | ||
| Q4 23 | $6.7M | — | ||
| Q3 23 | $10.8M | $405.5M |
| Q3 25 | — | $450.9M | ||
| Q2 25 | — | $460.8M | ||
| Q1 25 | — | $479.5M | ||
| Q3 24 | $231.0M | $555.5M | ||
| Q2 24 | $231.1M | — | ||
| Q1 24 | $220.3M | $296.8M | ||
| Q4 23 | $224.2M | — | ||
| Q3 23 | $226.6M | $389.6M |
| Q3 25 | — | $513.8M | ||
| Q2 25 | — | $519.0M | ||
| Q1 25 | — | $534.4M | ||
| Q3 24 | $339.7M | $600.8M | ||
| Q2 24 | $338.5M | — | ||
| Q1 24 | $321.8M | $326.6M | ||
| Q4 23 | $328.3M | — | ||
| Q3 23 | $320.3M | $414.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.6M | $-5.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-5.8M | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.0M | ||
| Q3 24 | $4.6M | $50.8M | ||
| Q2 24 | $19.1M | — | ||
| Q1 24 | — | $-49.7M | ||
| Q4 23 | — | — | ||
| Q3 23 | $14.5M | $-37.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.3M | ||
| Q3 24 | — | $50.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-37.1M |
| Q3 25 | — | — | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -192.8% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 1.40× | 1.37× | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 2.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCL
Segment breakdown not available.
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
